Ultragenyx Pharmaceutical Faces Securities Fraud Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy RARE?
Source: Businesswire
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against Ultragenyx Pharmaceutical on behalf of investors who purchased shares between August 3, 2023, and December 26, 2025, highlighting significant investor concerns regarding corporate transparency.
- Allegation Details: The lawsuit alleges that Ultragenyx misled investors by failing to disclose risks associated with its drug setrusumab, particularly regarding the potential failure to achieve a statistically significant reduction in annualized fracture rate, which could adversely affect stock performance.
- Investor Action: Investors have until April 6, 2026, to apply for lead plaintiff status, which is crucial as it may influence their rights to any recovery, underscoring the importance of the class action mechanism in securities litigation.
- Law Firm Overview: Kessler Topaz Meltzer & Check, LLP is a leading law firm focused on securities fraud class actions, representing both individual and institutional investors, demonstrating its expertise and influence in the securities litigation landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RARE
Wall Street analysts forecast RARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RARE is 61.65 USD with a low forecast of 35.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 23.880
Low
35.00
Averages
61.65
High
120.00
Current: 23.880
Low
35.00
Averages
61.65
High
120.00
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ultragenyx Pharmaceutical Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against Ultragenyx Pharmaceutical on behalf of investors who purchased shares between August 3, 2023, and December 26, 2025, highlighting significant investor concerns regarding corporate transparency.
- Allegation Details: The lawsuit alleges that Ultragenyx misled investors by failing to disclose risks associated with its drug setrusumab, particularly regarding the potential failure to achieve a statistically significant reduction in annualized fracture rate, which could adversely affect stock performance.
- Investor Action: Investors have until April 6, 2026, to apply for lead plaintiff status, which is crucial as it may influence their rights to any recovery, underscoring the importance of the class action mechanism in securities litigation.
- Law Firm Overview: Kessler Topaz Meltzer & Check, LLP is a leading law firm focused on securities fraud class actions, representing both individual and institutional investors, demonstrating its expertise and influence in the securities litigation landscape.
See More
Ultragenyx Pharmaceutical Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors that Ultragenyx Pharmaceutical is facing a class action lawsuit for securities violations related to transactions from August 3, 2023, to December 26, 2025, urging affected investors to contact the firm before April 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Ultragenyx made false and misleading statements, creating a falsely optimistic impression of its drug candidate's effects on Osteogenesis Imperfecta patients, resulting in significant investor losses once the truth was revealed.
- Clinical Trial Failure: The company failed to achieve a statistically significant reduction in annualized fracture rate in the Phase III ORBIT study, highlighting major misunderstandings regarding the drug's efficacy and exacerbating investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to discuss their rights, noting that the class has not yet been certified, meaning investors are not currently represented by an attorney.
See More
Ultragenyx Faces Class Action Lawsuit Over Stock Misrepresentation
- Class Action Initiation: Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit for alleged false statements regarding its stock from August 3, 2023, to December 26, 2025, with investors needing to apply as lead plaintiffs by April 6, 2025, indicating heightened legal risks for the company.
- Stock Price Plunge: Following the July 9, 2025 announcement that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock price fell over 25%, and a subsequent December 29 announcement of further study failures led to an additional 42% drop, reflecting market pessimism about the company's future.
- Details of Allegations: The lawsuit alleges that Ultragenyx and its executives made misleading statements regarding clinical trial results, failing to disclose associated risks, which may have resulted in significant investor losses, thereby impacting the company's reputation and future financing capabilities.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP, a leading class action firm, recovered over $916 million for investors in 2025, showcasing its strength in securities fraud and shareholder rights litigation, which could significantly influence the legal outcomes for Ultragenyx.
See More
Ultragenyx Pharmaceutical Class Action Lawsuit Announced
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) common stock between August 3, 2023, and December 26, 2025, indicating significant legal risks that may undermine shareholder confidence.
- Compensation Structure: Investors who bought shares during the class period may be entitled to compensation without any upfront costs, which could encourage more affected investors to join the lawsuit, potentially increasing the financial burden on the company.
- Counsel Selection Importance: The Rosen Law Firm emphasizes the necessity of choosing qualified legal representation, highlighting its past success in securing the largest securities class action settlement in 2017, thereby enhancing its credibility among investors.
- Case Details Unveiled: The lawsuit alleges that Ultragenyx made false or misleading statements regarding the potential of its drug setrusumab and the risks associated with study protocols, and if proven true, this could further damage the company's reputation and stock price.
See More
Class Action Lawsuit Announced for Ultragenyx Pharmaceutical
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Ultragenyx Pharmaceutical (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025, highlighting the legal risks the company faces.
- Compensation Structure: Investors joining the class action will not incur any out-of-pocket fees, as the lawsuit operates on a contingency fee basis, thereby reducing financial barriers and encouraging more affected parties to seek justice.
- Lawsuit Allegations: The lawsuit claims that Ultragenyx concealed significant adverse facts regarding setrusumab, asserting that while it increases bone density, it does not correlate with reduced fracture rates, leading to investor losses when the truth emerged.
- Counsel Selection Advice: Investors are advised to choose qualified legal representation, with Rosen Law Firm recognized for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, underscoring its credibility in the legal landscape.
See More
Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and certain officers, seeking damages for investors who acquired Ultragenyx securities between August 3, 2023, and December 26, 2025.
- False Statements Allegation: The complaint alleges that throughout the class period, defendants made false and/or misleading statements and failed to disclose risks associated with the Phase III Orbit study for Osteogenesis Imperfecta (OI), leading investors to have an unwarranted optimistic view of the study's results.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by April 6, 2026, to share in any potential recovery, with the assurance that participation does not require serving as lead plaintiff.
- Law Firm's Reputation: Bronstein, Gewirtz & Grossman, LLC is well-regarded in securities fraud class actions, having recovered hundreds of millions for investors nationwide, emphasizing its commitment to restoring investor capital and ensuring corporate accountability.
See More
Ultragenyx Pharmaceutical Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against Ultragenyx Pharmaceutical on behalf of investors who purchased shares between August 3, 2023, and December 26, 2025, highlighting significant investor concerns regarding corporate transparency.
- Allegation Details: The lawsuit alleges that Ultragenyx misled investors by failing to disclose risks associated with its drug setrusumab, particularly regarding the potential failure to achieve a statistically significant reduction in annualized fracture rate, which could adversely affect stock performance.
- Investor Action: Investors have until April 6, 2026, to apply for lead plaintiff status, which is crucial as it may influence their rights to any recovery, underscoring the importance of the class action mechanism in securities litigation.
- Law Firm Overview: Kessler Topaz Meltzer & Check, LLP is a leading law firm focused on securities fraud class actions, representing both individual and institutional investors, demonstrating its expertise and influence in the securities litigation landscape.
See More
Ultragenyx Pharmaceutical Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors that Ultragenyx Pharmaceutical is facing a class action lawsuit for securities violations related to transactions from August 3, 2023, to December 26, 2025, urging affected investors to contact the firm before April 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Ultragenyx made false and misleading statements, creating a falsely optimistic impression of its drug candidate's effects on Osteogenesis Imperfecta patients, resulting in significant investor losses once the truth was revealed.
- Clinical Trial Failure: The company failed to achieve a statistically significant reduction in annualized fracture rate in the Phase III ORBIT study, highlighting major misunderstandings regarding the drug's efficacy and exacerbating investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to discuss their rights, noting that the class has not yet been certified, meaning investors are not currently represented by an attorney.
See More
Ultragenyx Faces Class Action Lawsuit Over Stock Misrepresentation
- Class Action Initiation: Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit for alleged false statements regarding its stock from August 3, 2023, to December 26, 2025, with investors needing to apply as lead plaintiffs by April 6, 2025, indicating heightened legal risks for the company.
- Stock Price Plunge: Following the July 9, 2025 announcement that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock price fell over 25%, and a subsequent December 29 announcement of further study failures led to an additional 42% drop, reflecting market pessimism about the company's future.
- Details of Allegations: The lawsuit alleges that Ultragenyx and its executives made misleading statements regarding clinical trial results, failing to disclose associated risks, which may have resulted in significant investor losses, thereby impacting the company's reputation and future financing capabilities.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP, a leading class action firm, recovered over $916 million for investors in 2025, showcasing its strength in securities fraud and shareholder rights litigation, which could significantly influence the legal outcomes for Ultragenyx.
See More
Ultragenyx Pharmaceutical Class Action Lawsuit Announced
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) common stock between August 3, 2023, and December 26, 2025, indicating significant legal risks that may undermine shareholder confidence.
- Compensation Structure: Investors who bought shares during the class period may be entitled to compensation without any upfront costs, which could encourage more affected investors to join the lawsuit, potentially increasing the financial burden on the company.
- Counsel Selection Importance: The Rosen Law Firm emphasizes the necessity of choosing qualified legal representation, highlighting its past success in securing the largest securities class action settlement in 2017, thereby enhancing its credibility among investors.
- Case Details Unveiled: The lawsuit alleges that Ultragenyx made false or misleading statements regarding the potential of its drug setrusumab and the risks associated with study protocols, and if proven true, this could further damage the company's reputation and stock price.
See More
Class Action Lawsuit Announced for Ultragenyx Pharmaceutical
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Ultragenyx Pharmaceutical (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025, highlighting the legal risks the company faces.
- Compensation Structure: Investors joining the class action will not incur any out-of-pocket fees, as the lawsuit operates on a contingency fee basis, thereby reducing financial barriers and encouraging more affected parties to seek justice.
- Lawsuit Allegations: The lawsuit claims that Ultragenyx concealed significant adverse facts regarding setrusumab, asserting that while it increases bone density, it does not correlate with reduced fracture rates, leading to investor losses when the truth emerged.
- Counsel Selection Advice: Investors are advised to choose qualified legal representation, with Rosen Law Firm recognized for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, underscoring its credibility in the legal landscape.
See More
Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and certain officers, seeking damages for investors who acquired Ultragenyx securities between August 3, 2023, and December 26, 2025.
- False Statements Allegation: The complaint alleges that throughout the class period, defendants made false and/or misleading statements and failed to disclose risks associated with the Phase III Orbit study for Osteogenesis Imperfecta (OI), leading investors to have an unwarranted optimistic view of the study's results.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by April 6, 2026, to share in any potential recovery, with the assurance that participation does not require serving as lead plaintiff.
- Law Firm's Reputation: Bronstein, Gewirtz & Grossman, LLC is well-regarded in securities fraud class actions, having recovered hundreds of millions for investors nationwide, emphasizing its commitment to restoring investor capital and ensuring corporate accountability.
See More
